查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096801

開放性青光眼治療市場－2026-2032年全球市場預測

Open-Angle Glaucoma Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，開放性青光眼治療市場規模將成長至 187.3 億美元，複合年成長率為 9.06%。

主要市場統計數據
基準年 2025 102億美元
預計年份：2026年 111.2億美元
預測年份 2032 187.3億美元
複合年成長率 (%) 9.06%

開放性青光眼的治療對於預防這種疾病導致的不可逆轉性視力喪失至關重要，開放性青光眼通常為慢性進行性，早期無症狀，因此長期眼壓管理、治療依從性和早期療育在眼科護理中至關重要。目前的治療策略包括前列腺素類似物、 BETA阻斷劑、α受體促效劑、碳酸酐酶抑制劑、Rho激酶抑制劑、固定劑量組合藥物、選擇性小梁網整型術以及在藥物治療效果不佳時輔助性治療降低眼壓的手術治療。

在臨床實踐中，減輕治療負擔並延緩視神經損傷的需求正在影響治療策略。不含防腐劑的製劑、緩釋藥物遞送系統、神經保護研究、微創青光眼手術輔助性治療以及支持用藥依從性的數位化工具正日益影響著治療決策。保險公司、醫療服務提供者和監管機構也更加重視真實世界的治療效果、病患依從性、老年人的安全性以及眼科醫療服務的公平可及性。隨著人口老化導致青光眼盛行率上升，該領域正朝著更個人化、永續和以患者為中心的治療模式轉變。

治療環境的變革性變化

開放性青光眼的治療模式正經歷結構性轉變，從主要以症狀控制為主的慢性治療轉向綜合疾病管理。傳統上，眼藥水是治療的基礎，但即使症狀輕微，患者也往往需要終身每日用藥，導致藥物依從性問題頻繁發生。因此，人們對固定劑量組合藥物製劑、每日一次給藥方案、不含防腐劑的眼科製劑以及旨在簡化治療並最大限度減少眼表毒性的緩釋技術越來越感興趣。

人工智慧（AI）的累積影響

人工智慧 (AI) 正逐步影響開放性青光眼的治療，其作用體現在診斷、風險分層、監測和個人化治療等方面。 AI 驅動的光學同調斷層掃描(OCT)、眼底成像、視野檢查和電子健康記錄分析有助於早期發現結構和功能進展。早期發現至關重要，因為在視神經損傷有限且能在嚴重視力喪失發生之前設定目標眼壓時，治療性介入最為有效。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

亞太地區由於老年人口眾多、篩檢活動活性化以及慢性眼科疾病負擔日益加重，對開開放性青光眼的治療至關重要。在日本、中國、印度、韓國和澳大利亞，隨著眼科醫療基礎設施的不斷改善和人們對可預防性失明的認知不斷提高，長期眼壓管理的需求日益成長。然而，都市區地區在醫療服務取得方面仍然存在差距，而治療費用的可負擔性、學名藥的可及性、擴充性的篩檢以及遠距眼科醫療服務是擴大治療涵蓋範圍的關鍵因素。

重點區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團與北約

在東南亞國協，隨著醫療衛生系統不斷擴展其專科網路和篩檢項目，預防性失明和慢性眼科疾病的管理日益受到重視。東協地區開放性青光眼治療的需求主要受人口老化、大都會圈醫療資源分配不均以及對價格合理的降眼壓療法的需求等因素所驅動。公私合營合作、遠距眼科醫療、社區眼科保健計畫以及藥局服務能夠支持不同醫療衛生系統之間早期治療的持續發展。

主要國家概況：美國、加拿大、墨西哥、巴西、英國、英國、法國、俄羅斯、義大利、西班牙、中國、印度、日本、澳洲、韓國

美國擁有非常完善的開放性青光眼治療體系，這得益於先進的診斷技術、許多專科醫生、臨床指南的採納以及藥物治療、雷射治療和輔助性治療的廣泛應用。加拿大也重視實證治療，並透過省級醫療保健系統提供醫療服務，但專科服務的地理分佈可能會影響治療的及時性。在墨西哥，人們對青光眼的認知和獲得眼科醫療服務的途徑正在不斷提高，但高昂的治療費用和診斷延誤仍然是嚴峻的挑戰。在巴西，眼科醫療需求量龐大，公共和私人醫療保健系統都支持患者獲得治療，但地區差異會影響治療的連續性。

為行業領導者提供的實用建議

產業領導者應優先考慮能夠提高長期用藥依從性、簡化給藥流程並改善眼表耐受性的治療和給藥模式。不含防腐劑的產品、固定劑量組合藥物、緩釋製劑以及具有獨特作用機制的療法，都應與真實世界數據相符，這些數據應能證明其持久性、安全性、持續性和患者報告的益處。

調查方法

評估開放性青光眼治療方案的調查方法結合了二手資料研究、一手檢驗、臨床證據審查和結構化分析解讀。二手資料研究包括同行評審的眼科文獻、臨床指南、監管文件、公共衛生資訊來源、藥物警戒參考資料、疾病負擔研究和真實世界證據出版物。這些資訊來源有助於評估治療模式、治療分類、診療路徑、技術應用和可近性等因素。

結論

開放性青光眼的治療正朝著更永續、更個人化、更注重藥物依從性的方向發展。雖然降低眼壓仍然是治療的核心目標，但更廣泛的治療方案現在包括改良的藥物配方、固定劑量組合藥物、雷射聯合治療、微創輔助手術以及人工智慧驅動的疾病監測。這些進展反映了臨床現實：長期治療的成功取決於早期發現、持續穩定的治療以及在病情進展風險較高時及時強化治療。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：開放性青光眼治療市場：依藥物類別分類

  • α受體促效劑
  • BETA阻斷劑
    • 倍他索
    • 甲羥孕酮
    • 蒂莫羅爾
  • 碳酸酐酶抑制劑
  • 固定劑量組合藥物
  • 前列腺素類似物
    • Bimatoprost
    • 拉坦前列素
    • 塔福普羅斯特
    • 曲前列素
  • Rho激酶抑制劑
  • 膽鹼能促效劑

第8章：開放性青光眼治療市場：依治療類型分類

  • 聯合治療
    • BETA阻斷劑與攝護腺素
    • 碳酸酐酶抑制劑和BETA阻斷劑
  • 單藥治療

第9章：開放性青光眼治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 外用

第10章：開放性青光眼治療市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 專科藥房
  • 郵購藥房

第11章：開放性青光眼治療市場：依最終用戶分類

  • 醫院
    • 三級醫療機構
    • 當地醫院
  • 門診手術中心
  • 眼科診所
  • 驗光診所
  • 學術和研究機構

第12章：開放性青光眼治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：開放性青光眼治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章開放性青光眼治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbisko Therapeutics Co., Ltd.
  • AbbVie Inc.
  • Aerie Pharmaceuticals, Inc.
  • Ajanta Pharma Limited
  • Akorn Operating Company LLC
  • Alcon Inc.
  • Amorphex Therapeutics Holdings, Inc.
  • Apotex Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Cipla Limited
  • EyePoint Pharmaceuticals, Inc.
  • Genentech, Inc.
  • Glaukos Corporation
  • Harrow, Inc.
  • iVeena Holdings, Inc.
  • Johnson & Johnson Services, Inc.
  • Kowa Company, Ltd.
  • Lupin Limited
  • Merck & Co., Inc.
  • Nicox SA
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Ocuphire Pharma, Inc.
  • Pfizer Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-957C47F9384B

The Open-Angle Glaucoma Therapeutics Market is projected to grow by USD 18.73 billion at a CAGR of 9.06% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.20 billion
Estimated Year [2026] USD 11.12 billion
Forecast Year [2032] USD 18.73 billion
CAGR (%) 9.06%

Open-angle glaucoma therapeutics are central to preventing irreversible vision loss in one of the world's leading causes of blindness. Open-angle glaucoma is typically chronic, progressive, and asymptomatic in early stages, making long-term intraocular pressure control, treatment adherence, and early intervention critical priorities for ophthalmology care. Current therapeutic strategies include prostaglandin analogs, beta-blockers, alpha agonists, carbonic anhydrase inhibitors, rho kinase inhibitors, fixed-dose combinations, selective laser trabeculoplasty, and surgical adjuncts that support pressure reduction when pharmacologic control is insufficient.

The clinical landscape is shaped by the need to delay optic nerve damage while reducing treatment burden. Preservative-free formulations, sustained-release drug delivery systems, neuroprotection research, minimally invasive glaucoma surgery adjunctive therapy, and digital adherence tools are increasingly influencing therapeutic decision-making. Payers, providers, and regulators are also emphasizing real-world outcomes, patient persistence, safety in elderly populations, and equitable access to ophthalmic care. As glaucoma prevalence rises with population aging, the sector is moving toward more personalized, durable, and patient-centric treatment models.

Transformative Shifts in the Therapeutics Landscape

The open-angle glaucoma therapeutics landscape is undergoing a structural shift from symptom-managed chronic treatment toward integrated disease control. Historically, topical eye drops formed the foundation of therapy, but adherence challenges remain well documented because patients often require lifelong, daily dosing despite minimal symptoms. This has accelerated interest in fixed-dose combinations, once-daily regimens, preservative-free ophthalmic products, and sustained-release technologies designed to simplify therapy while limiting ocular surface toxicity.

Clinical practice is also becoming more algorithm-driven, with ophthalmologists increasingly combining pharmacologic therapy, selective laser trabeculoplasty, and minimally invasive procedures earlier in the care pathway for selected patients. Evidence supporting laser trabeculoplasty as an effective first-line or adjunctive intervention has encouraged broader adoption in health systems seeking durable intraocular pressure reduction and reduced dependence on topical medications. At the same time, the therapeutic pipeline is expanding beyond conventional pressure-lowering mechanisms to include trabecular outflow modulation, nitric oxide donation, rho kinase inhibition, and investigative neuroprotective approaches.

Another major transformation is the growing role of patient stratification. Disease severity, target intraocular pressure, corneal thickness, optic nerve status, comorbidities, ocular surface disease, medication tolerance, and socioeconomic access now influence therapy selection more explicitly. This is pushing the industry toward differentiated formulations, evidence-based sequencing, and adherence-enabling care models that address both clinical efficacy and patient behavior.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence open-angle glaucoma therapeutics by improving diagnosis, risk stratification, monitoring, and treatment personalization. AI-enabled analysis of optical coherence tomography, fundus imaging, visual field testing, and electronic health records can support earlier identification of structural and functional progression. Earlier detection is clinically significant because therapeutic intervention is most effective when optic nerve damage is limited and target pressure can be established before advanced vision loss occurs.

AI also has practical implications for treatment optimization. Predictive models may help clinicians identify patients at higher risk of rapid progression, poor adherence, or insufficient intraocular pressure response, enabling more proactive escalation to combination therapy, laser treatment, sustained-release options, or surgical referral. In clinical research, AI can enhance patient selection, endpoint analysis, imaging interpretation, and real-world evidence generation, supporting more precise evaluation of therapeutic durability and safety.

The cumulative impact of AI will depend on validation, explainability, bias reduction, cybersecurity, and integration into ophthalmology workflows. Datasets must reflect diverse populations because glaucoma risk and treatment access differ by ancestry, age, geography, and health system capacity. When responsibly deployed, AI can strengthen open-angle glaucoma therapeutics by linking early detection, individualized treatment pathways, and longitudinal disease surveillance into a more efficient care continuum.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

Asia-Pacific is a critical region for open-angle glaucoma therapeutics due to large aging populations, increasing screening activity, and a growing burden of chronic eye disease. Japan, China, India, South Korea, and Australia are seeing greater demand for long-term intraocular pressure management, supported by expanding ophthalmology infrastructure and rising awareness of preventable blindness. However, access remains uneven across urban and rural settings, making affordability, generic availability, scalable screening, and teleophthalmology central to therapeutic uptake.

North America demonstrates advanced adoption of innovative glaucoma therapies, driven by established ophthalmology networks, widespread diagnostic imaging, clinical guideline utilization, and access to laser and surgical adjuncts. The United States and Canada emphasize early diagnosis, medication adherence, preservative-free formulations, and integration of real-world evidence into care quality programs. Latin America continues to improve glaucoma care through specialist expansion and public health awareness, although economic disparities, out-of-pocket costs, and delayed diagnosis remain important barriers to sustained treatment.

Europe benefits from structured healthcare systems, established reimbursement pathways, and strong adherence to evidence-based glaucoma management. Countries across Western Europe show high utilization of diagnostic technologies and combination treatment strategies, while Eastern Europe continues to strengthen access to modern pharmacologic and procedural care. The Middle East is investing in tertiary eye care, digital health infrastructure, and specialist services, particularly in high-income Gulf states, while broader regional access varies by national healthcare capacity. Africa faces significant gaps in early diagnosis and continuous treatment access, yet the region has high clinical relevance because glaucoma-related blindness is often detected late; community screening, affordable medicines, task-sharing, and training of eye care professionals are key priorities.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN countries are increasingly prioritizing preventable blindness and chronic eye disease management as healthcare systems expand specialist capacity and screening programs. Demand for open-angle glaucoma therapeutics in ASEAN is influenced by demographic aging, uneven access between metropolitan and rural areas, and the need for affordable pressure-lowering therapies. Public-private initiatives, teleophthalmology, community eye health programs, and pharmacy access can support earlier treatment continuity across diverse health systems.

The GCC shows strong potential for advanced glaucoma care due to investment in specialist hospitals, digital health systems, and tertiary ophthalmology services. High rates of metabolic disease, aging populations, and health system modernization reinforce demand for comprehensive eye care, including pharmacologic therapy, laser trabeculoplasty, and surgical adjuncts. The European Union provides one of the most structured environments for evidence-based glaucoma therapeutics, with regulatory emphasis on safety, quality, pharmacovigilance, and equitable access across member states, although reimbursement rules, formulary decisions, and prescribing practices vary by country.

BRICS countries represent a diverse set of therapeutic environments, combining large patient populations, growing domestic pharmaceutical capacity, and significant access challenges. China, India, Brazil, Russia, and South Africa differ in screening infrastructure and reimbursement models, but all face pressure to expand early diagnosis and long-term treatment adherence. G7 countries tend to lead in advanced diagnostics, clinical trial activity, regulatory rigor, and adoption of innovative delivery systems, while NATO member states overlap significantly with high-income healthcare systems in North America and Europe, where ophthalmology care is increasingly guided by integrated diagnostics, standardized clinical pathways, and quality-driven outcomes.

Key Country Insights: United States, Canada, Mexico, Brazil, UK, Germany, France, Russia, Italy, Spain, China, India, Japan, Australia & South Korea

The United States remains a highly developed environment for open-angle glaucoma therapeutics, supported by advanced diagnostics, specialist availability, clinical guideline adoption, and broad use of pharmacologic, laser, and surgical adjunctive options. Canada similarly emphasizes evidence-based treatment and access through provincial healthcare systems, although geographic distribution of specialist services can affect timely care. Mexico is advancing glaucoma awareness and ophthalmology access, yet affordability and delayed diagnosis remain relevant challenges. Brazil has a large ophthalmic care need, with public and private systems supporting treatment access while regional disparities influence continuity of care.

In Europe, the United Kingdom applies structured clinical guidance and referral pathways that support standardized glaucoma management. Germany benefits from strong diagnostic infrastructure and specialist care, while France emphasizes regulated access to ophthalmic medicines and chronic disease management. Italy and Spain maintain broad ophthalmology capabilities but face capacity pressures from aging populations. Russia has established ophthalmology expertise in major urban centers, though access consistency can vary across regions.

China faces a substantial glaucoma care burden due to population size and aging, with increasing investment in diagnostic capacity, specialist services, and domestic therapeutic availability. India has a major unmet need because many cases are detected late, making affordable medicines, screening expansion, and adherence support especially important. Japan has a mature glaucoma therapeutics environment with high awareness of aging-related eye disease and strong diagnostic adoption. Australia benefits from organized eye care services and public health attention to preventable blindness, particularly in remote and Indigenous communities. South Korea combines advanced healthcare infrastructure, high technology adoption, and specialist-led glaucoma care, supporting use of modern diagnostics and individualized treatment strategies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies and delivery models that improve long-term adherence, reduce dosing complexity, and address ocular surface tolerability. Preservative-free products, fixed-dose combinations, sustained-release platforms, and therapies with differentiated mechanisms should be aligned with real-world evidence demonstrating durability, safety, persistence, and patient-reported benefits.

Stakeholders should also invest in integrated glaucoma care pathways that connect screening, diagnosis, treatment initiation, monitoring, and escalation. Partnerships with eye care providers, pharmacies, digital health platforms, academic centers, and public health programs can improve early identification and continuity of therapy. In lower-access regions, affordability strategies, local manufacturing partnerships, professional training, and simplified treatment protocols can expand reach without compromising quality.

AI-enabled tools should be pursued responsibly, with clinically validated algorithms, diverse datasets, explainable outputs, and workflow integration that supports rather than replaces ophthalmologist judgment. Regulatory and market access strategies should emphasize patient-centered outcomes, adherence benefits, reduced progression risk, and health system efficiency. Competitive differentiation will increasingly depend on demonstrating not only intraocular pressure reduction but also convenience, tolerability, durability, equitable access, and measurable value in everyday clinical practice.

Research Methodology

The research methodology for evaluating open-angle glaucoma therapeutics combines secondary research, primary validation, clinical evidence review, and structured analytical interpretation. Secondary research includes peer-reviewed ophthalmology literature, clinical guidelines, regulatory documents, public health sources, pharmacovigilance references, disease burden studies, and real-world evidence publications. These sources support assessment of treatment patterns, therapeutic classes, care pathways, technology adoption, and access considerations.

Primary research typically includes interviews and discussions with ophthalmologists, optometrists, clinical researchers, hospital procurement stakeholders, pharmacists, payers, and policy experts. These inputs help validate treatment adoption trends, adherence barriers, prescribing preferences, reimbursement dynamics, and regional access conditions. Clinical evidence is evaluated across efficacy, safety, durability, dosing burden, ocular tolerability, contraindications, and applicability to different patient populations.

Analytical triangulation is applied to compare source consistency, identify regional variations, and distinguish established evidence from emerging hypotheses. Particular attention is given to avoiding unsupported assumptions, especially in areas such as therapeutic adoption, access barriers, AI integration, and procedural adjunct use. The methodology emphasizes verified, data-backed interpretation without relying on market sizing, market share, or forecasting claims.

Conclusion

Open-angle glaucoma therapeutics are evolving toward more durable, individualized, and adherence-focused care. While intraocular pressure reduction remains the core therapeutic objective, the broader treatment landscape now includes improved formulations, fixed-dose combinations, sustained-release approaches, laser therapy integration, minimally invasive procedural adjuncts, and AI-supported disease monitoring. These developments reflect the clinical reality that long-term success depends on early detection, sustained treatment persistence, and timely escalation when progression risk is high.

Regional and country-level differences in healthcare infrastructure, affordability, specialist availability, and screening capacity continue to shape therapeutic access. High-income markets are advancing toward precision monitoring and innovative delivery systems, while emerging and underserved regions require scalable solutions that improve diagnosis and continuity of care. Industry participants that focus on patient-centered outcomes, real-world durability, equitable access, and validated digital integration will be best positioned to support the next phase of glaucoma care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Open-Angle Glaucoma Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Alpha Agonists
  • 7.3. Beta Blockers
    • 7.3.1. Betaxolol
    • 7.3.2. Metipranolol
    • 7.3.3. Timolol
  • 7.4. Carbonic Anhydrase Inhibitors
  • 7.5. Fixed Dose Combinations
  • 7.6. Prostaglandin Analogues
    • 7.6.1. Bimatoprost
    • 7.6.2. Latanoprost
    • 7.6.3. Tafluprost
    • 7.6.4. Travoprost
  • 7.7. Rho Kinase Inhibitors
  • 7.8. Cholinergic Agents

8. Open-Angle Glaucoma Therapeutics Market, by Therapy Type

  • 8.1. Introduction
  • 8.2. Combination Therapy
    • 8.2.1. Beta Blocker & Prostaglandin
    • 8.2.2. Carbonic Anhydrase Inhibitor & Beta Blocker
  • 8.3. Monotherapy

9. Open-Angle Glaucoma Therapeutics Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Topical

10. Open-Angle Glaucoma Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies
  • 10.5. Specialty Pharmacies
  • 10.6. Mail-Order Pharmacies

11. Open-Angle Glaucoma Therapeutics Market, by End User

  • 11.1. Introduction
  • 11.2. Hospitals
    • 11.2.1. Tertiary Care Hospitals
    • 11.2.2. Community Hospitals
  • 11.3. Ambulatory Surgical Centers
  • 11.4. Ophthalmology Specialty Clinics
  • 11.5. Optometry Practices
  • 11.6. Academic & Research Centers

12. Open-Angle Glaucoma Therapeutics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Open-Angle Glaucoma Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Open-Angle Glaucoma Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbisko Therapeutics Co., Ltd.
  • 16.2. AbbVie Inc.
  • 16.3. Aerie Pharmaceuticals, Inc.
  • 16.4. Ajanta Pharma Limited
  • 16.5. Akorn Operating Company LLC
  • 16.6. Alcon Inc.
  • 16.7. Amorphex Therapeutics Holdings, Inc.
  • 16.8. Apotex Inc.
  • 16.9. Astellas Pharma Inc.
  • 16.10. Bausch Health Companies Inc.
  • 16.11. Cipla Limited
  • 16.12. EyePoint Pharmaceuticals, Inc.
  • 16.13. Genentech, Inc.
  • 16.14. Glaukos Corporation
  • 16.15. Harrow, Inc.
  • 16.16. iVeena Holdings, Inc.
  • 16.17. Johnson & Johnson Services, Inc.
  • 16.18. Kowa Company, Ltd.
  • 16.19. Lupin Limited
  • 16.20. Merck & Co., Inc.
  • 16.21. Nicox S.A.
  • 16.22. Novartis AG
  • 16.23. Ocular Therapeutix, Inc.
  • 16.24. Ocuphire Pharma, Inc.
  • 16.25. Pfizer Inc.
  • 16.26. Santen Pharmaceutical Co., Ltd.
  • 16.27. Senju Pharmaceutical Co., Ltd.
  • 16.28. Sun Pharmaceutical Industries Ltd.
  • 16.29. Teva Pharmaceutical Industries Ltd.
  • 16.30. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALPHA AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALPHA AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALPHA AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BETA BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BETAXOLOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BETAXOLOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BETAXOLOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL METIPRANOLOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL METIPRANOLOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL METIPRANOLOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TIMOLOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TIMOLOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TIMOLOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FIXED DOSE COMBINATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FIXED DOSE COMBINATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FIXED DOSE COMBINATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROSTAGLANDIN ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROSTAGLANDIN ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTAGLANDIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIMATOPROST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIMATOPROST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIMATOPROST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LATANOPROST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LATANOPROST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LATANOPROST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TAFLUPROST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TAFLUPROST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TAFLUPROST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRAVOPROST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRAVOPROST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRAVOPROST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RHO KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RHO KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RHO KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHOLINERGIC AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHOLINERGIC AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHOLINERGIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BETA BLOCKER & PROSTAGLANDIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BETA BLOCKER & PROSTAGLANDIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BETA BLOCKER & PROSTAGLANDIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARBONIC ANHYDRASE INHIBITOR & BETA BLOCKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARBONIC ANHYDRASE INHIBITOR & BETA BLOCKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARBONIC ANHYDRASE INHIBITOR & BETA BLOCKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MAIL-ORDER PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MAIL-ORDER PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MAIL-ORDER PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OPHTHALMOLOGY SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OPHTHALMOLOGY SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OPHTHALMOLOGY SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OPTOMETRY PRACTICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OPTOMETRY PRACTICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL OPTOMETRY PRACTICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ACADEMIC & RESEARCH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACADEMIC & RESEARCH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ACADEMIC & RESEARCH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 183. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 213. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 223. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 240. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 250. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 283. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 284. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 290. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 292. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 300. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 301. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 302. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 303. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 304. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 310. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 312. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 313. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 314. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 316. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 318. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 320. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 322. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 323. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 324. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 326. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, B